N-(thiazol-4-yl)acetamide | 7041-83-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(thiazol-4-yl)acetamide
• 英文别名: N-thiazol-4-yl-acetamide；N-Thiazol-4-yl-acetamid；4-acetamidothiazole；4-Acetamino-1,3-thiazol；4-Acetaminothiazol；N-(1,3-thiazol-4-yl)acetamide
• CAS: 7041-83-0
• 化学式: C₅H₆N₂OS
• mdl: MFCD03428581
• 分子量: 142.181
• InChiKey: GNRPCBOCZFRWLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(thiazol-4-yl)acetamide 在 N-溴代丁二酰亚胺(NBS) 、 四磷十氧化物 、 potassium carbonate 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 溶剂黄146 为溶剂， 反应 24.0h， 生成 5,6-dimethyl-8-propyl-1-thia-3,4,7,8a-tetraaza-as-indacene
  参考文献：
  名称：

  [EN] NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  [FR] NOUVEAUX COMPOSÉS INHIBITEURS DE PHOSPHODIESTÉRASE DE TYPE 10A

  摘要：

  本发明涉及公式I的化合物，其N-氧化物、互变异构体、前药和其药学上可接受的盐。在公式I中，变量X、Y、Q1、Q2具有以下含义：X为C-R3或N；Q1为S或O，Q2为C-R4或N，Q2通过双键与X连接，而Q1通过单键与X连接；或者Q2为S或O，Q1为C-R4或N，Q1通过双键与X连接，而Q2通过单键与X连接；Y为C-R5或N；在公式I中，变量R1、R2、R3、R4和R5的定义如索权中所述。公式I的化合物、N-氧化物、互变异构体、前药和其药学上可接受的盐是磷酸二酯酶10A的抑制剂，用于制备药物，并因此适用于治疗或控制神经系统疾病和精神疾病，缓解与这些疾病相关的症状，并降低这些疾病的风险。

  公开号：

  WO2014041175A1
• 作为产物：
  描述：

  1-(2-methyl-thiazol-4-yl)-ethanone oxime 在 五氯化磷 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以73%的产率得到N-(thiazol-4-yl)acetamide
  参考文献：
  名称：

  Thiazolo[4,5-d]thiazole—a new domain for potential optoelectronic application

  摘要：

  A novel heterocyclic moiety based on thiazolo[4.5-d]thiazole was prepared via a six-step synthesis from butane-2,3-dione. This thiazolothiazole compound was further derivatized to afford either neutral conjugated condensation products or analogous N-alkyl salts. The obtained derivatives represent dipolar structures expressed as A-pi-D (push-pull compounds) as well as quadrupolar D-pi-A-pi-D structures. Both types of compound show intramolecular charge transfer and therefore could be suitable for nonlinear optical applications. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.08.110

文献信息

• Thiazole compositions
  申请人：John Wyeth & Brother Limited

  公开号：US04134984A1

  公开（公告）日：1979-01-16

  The invention relates to the use of thiazoles in the treatment of ulcers and/or hypersecretion in mammals. The invention also provides in a preferred aspect a pharmaceutical composition for use in the treatment of ulcers or hypersecretion comprising a compound of formula I ##STR1## where R.sup.1 is hydrogen, alkyl of 1-6 carbon atoms, or phenyl, R is hydrogen, n-alkyl of 1-4 carbon atoms (which may be substituted by chlorine), or cyclopropyl, R.sup.3 is hydrogen or COR.sup.4 where R.sup.4 is as defined for R and R and R.sup.4 may be the same or different and a pharmaceutically acceptable carrier.

  本发明涉及在哺乳动物中治疗溃疡和/或高分泌的噻唑类化合物的使用。该发明在首选方面还提供了一种用于治疗溃疡或高分泌的药物组合物，其包括式I的化合物：##STR1## 其中R.sup.1是氢，1-6个碳原子的烷基或苯基，R是氢，1-4个碳原子的n-烷基（可以被氯取代），或环丙基，R.sup.3是氢或COR.sup.4，其中R.sup.4与R和R.sup.4的定义相同，R和R.sup.4可以相同也可以不同，并且具有药学上可接受的载体。
• Über Derivate des 4-Aminothiazols
  作者：H. Erlenmeyer、Dieter Markees

  DOI：10.1002/hlca.19460290534

  日期：——

  No abstract is available for this article.

  本文没有摘要。
• Certain 4-formamidothiazoles
  申请人：John Wyeth & Brother Ltd.

  公开号：US04249012A1

  公开（公告）日：1981-02-03

  The invention relates to the use of thiazoles in the treatment of ulcers and/or hypersecretion in mammals. The invention also provides in a preferred aspect a pharmaceutical composition for use in the treatment of ulcers or hypersecretion comprising a compound of formula I ##STR1## where R.sup.1 is hydrogen, alkyl of 1-6 carbon atoms, or phenyl, R is hydrogen, n-alkyl of 1-4 carbon atoms (which may be substituted by chlorine), or cyclopropyl, R.sup.3 is hydrogen or COR.sup.4 where R.sup.4 is as defined for R and R and R.sup.4 may be the same or different and a pharmaceutically acceptable carrier.

  该发明涉及在哺乳动物中治疗溃疡和/或过度分泌的噻唑类化合物的使用。该发明还提供了一种首选方面的制药组合物，用于治疗溃疡或过度分泌，包括式I的化合物：##STR1## 其中R1为氢，1-6个碳原子的烷基或苯基，R为氢，1-4个碳原子的n-烷基（可以被氯取代）或环丙基，R3为氢或COR4，其中R4如R和R定义，R和R4可以相同或不同，以及一种药学上可接受的载体。
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：AbbVie Inc.

  公开号：US20140107126A1

  公开（公告）日：2014-04-17

  The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q 1 , Q 2 have the following meanings: X is C—R 3 or N; Q 1 is S or O and Q 2 is C—R 4 or N and Q 2 is connected to X via a double bond while Q 1 is connected to X via a single bond; or Q 2 is S or O and Q 1 is C—R 4 or N and Q 1 is connected to X via a double bond while Q 2 is connected to X via a single bond; Y is C—R 5 or N; where in formula I the variables R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the claims The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式I的化合物，其N-氧化物、互变异构体、前药及其药学上可接受的盐。在公式I中，变量X、Y、Q1、Q2具有以下含义：X为C—R3或N；Q1为S或O，Q2为C—R4或N，而Q2通过双键与X连接，Q1通过单键与X连接；或者Q2为S或O，Q1为C—R4或N，而Q1通过双键与X连接，Q2通过单键与X连接；Y为C—R5或N。在公式I中，变量R1、R2、R3、R4和R5如权利要求所定义。公式I的化合物、N-氧化物、互变异构体、前药及其药学上可接受的盐是磷酸二酯酶10A的抑制剂，用于制造药物，因此适用于治疗或控制神经系统疾病和精神疾病，改善与此类疾病相关的症状并降低此类疾病的风险。
• Inhibitor compounds of phosphodiesterase type 10A
  申请人：Abbott GmbH & Co. KG

  公开号：US09388180B2

  公开（公告）日：2016-07-12

  The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q1, Q2 have the following meanings: X is C—R3 or N; Q1 is S or O and Q2 is C—R4 or N and Q2 is connected to X via a double bond while Q1 is connected to X via a single bond; or Q2 is S or O and Q1 is C—R4 or N and Q1 is connected to X via a double bond while Q2 is connected to X via a single bond; Y is C—R5 or N; where in formula I the variables R1, R2, R3, R4 and R5 are as defined in the claims The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式I的化合物，其N-氧化物、互变异构体、前药和其药学上可接受的盐，其中公式I中的变量X、Y、Q1、Q2具有以下含义：X为C—R3或N；Q1为S或O，Q2为C—R4或N，且Q2通过双键与X连接，而Q1通过单键与X连接；或者Q2为S或O，Q1为C—R4或N，且Q1通过双键与X连接，而Q2通过单键与X连接；Y为C—R5或N；在公式I中，变量R1、R2、R3、R4和R5如权利要求所定义。公式I的化合物、N-氧化物、互变异构体、前药和其药学上可接受的盐是磷酸二酯酶10A的抑制剂，可用于制造药物，因此适用于治疗或控制神经系统和精神系统疾病，改善与此类疾病相关的症状并降低此类疾病的风险。